New combo therapy aims to shrink tumors before esophageal cancer surgery
NCT ID NCT03784326
Summary
This study is testing whether adding immunotherapy drugs to standard chemotherapy before surgery can better control cancer in the esophagus or where the stomach meets the esophagus. The goal is to shrink the tumor as much as possible before an operation to remove it. Researchers are looking at how well the treatment works and how safe it is for patients with localized cancer that hasn't spread to distant parts of the body.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLINICAL STAGE II ESOPHAGEAL ADENOCARCINOMA AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.